[Form 4] GENPACT LIMITED Insider Trading Activity

Rhea-AI Filing Summary

Genpact Limited insider Form 4: Senior Vice President Riju Vashisht reported two open-market sales of Genpact (G) common shares on 08/22/2025. The first sale disposed of 17,608 shares at a weighted average price of $45.61, leaving 130,201 shares beneficially owned. The second sale disposed of 7,931 shares at a weighted average price of $45.57, leaving 122,270 shares beneficially owned. The combined number of shares sold was 25,539. The form notes the price ranges for the sales and discloses the reporting person holds 4,154 shares via the Employee Stock Purchase Plan, including 160 shares acquired since the prior Form 4. The filing was signed by an attorney-in-fact on 08/25/2025.

Positive

• Timely and detailed disclosure of insider sales with weighted-average price ranges provided
• ESPP holdings quantified (4,154 shares total, 160 shares acquired since prior Form 4), improving transparency

Negative

• Substantial insider selling of 25,539 shares on 08/22/2025, which reduces the reporting person's direct holdings
• Two different post-transaction ownership figures (130,201 and 122,270) present without contextual explanation beyond the transactions

Insights

Securities Analyst

TL;DR: Officer sold 25,539 shares in two transactions at ~$45.6 each; holdings remain over 120k shares.

The disclosed sales are open-market dispositions on 08/22/2025 with weighted average prices and a provided price range. The total sale amount and remaining beneficial ownership are explicitly stated, allowing investors to quantify insider liquidity without speculation about motive. The filing complies with Section 16 disclosure requirements and includes ESPP holdings reconciliation.

Corporate Governance Expert

TL;DR: Timely Form 4 filing shows routine insider selling; disclosure includes ESPP details and attorney-in-fact signature.

The report identifies the reporting person as a Senior Vice President and indicates the Form was filed by one reporting person. The presence of an attorney-in-fact signature and explicit explanations of weighted average prices and ESPP share counts support transparency. There is no additional governance detail or indication of unusual trading patterns in the document itself.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vashisht Riju

(Last) (First) (Middle)

C/O GENPACT LLC

521 FIFTH AVENUE, 14TH FLOOR

(Street)

NEW YORK NY 10175

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Genpact LTD [ G ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/22/2025		S		17,608	D	$45.61(1)	130,201(2)	D
Common Shares	08/22/2025		S		7,931	D	$45.57(3)	122,270(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price in Column 4 is a weighted average price. The actual sales prices for these transactions ranged from $45.60 to $45.66. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

2. Includes 160 shares acquired under the Genpact Employee Stock Purchase Plan ("ESPP") since the reporting person's Form 4 filed on March 13, 2025. The reporting person currently holds a total of 4,154 shares under the ESPP.

3. The price in Column 4 is a weighted average price. The actual sales prices for these transactions ranged from $45.56 to $45.59. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Remarks:

	/s/ Thomas D. Scholtes, as Attorney-in-fact for Riju Vashisht	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Genpact (G) shares did Riju Vashisht sell on 08/22/2025?

The filing reports two sales totaling 25,539 shares: 17,608 and 7,931 shares.

At what prices were the Genpact shares sold in the Form 4?

Sales were at weighted average prices of $45.61 (range $45.60–$45.66) and $45.57 (range $45.56–$45.59).

What were Riju Vashisht's reported beneficial holdings after the transactions?

The Form 4 reports 130,201 shares after the first reported sale and 122,270 shares after the second reported sale.

Does the filing disclose any Employee Stock Purchase Plan (ESPP) holdings?

Yes. The reporting person holds 4,154 shares under the ESPP, including 160 shares acquired since the prior Form 4.

Who signed the Form 4 and when was it signed?

The Form 4 was signed by Thomas D. Scholtes as attorney-in-fact for Riju Vashisht on 08/25/2025.